Navigation Links
Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Date:1/29/2008

- New Clinical Trial Will Evaluate Anti-Tumor Activity of Bavituximab in

Combination with Docetaxel -

TUSTIN, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient screening has begun in a clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in advanced breast cancer. The multi-center clinical trial is being conducted in the Republic of Georgia.

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"We are delighted that patient screening has begun in this Phase II study that provides us with an excellent opportunity to further evaluate the potential efficacy of bavituximab in combination with chemotherapy in treating breast cancer," said Steven W. King, president and CEO of Peregrine. "This trial should allow us to build on the encouraging results we observed in breast cancer patients in an earlier bavituximab
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,, IRVINE,Calif.,Nov.24/PRNewswire-FirstCall...llyinvasivetreatmentsforaorticdisorders,announcedt...oceedingsin,thepatentinfringementlawsuitbroughtaga...heUnitedStatesDistrictCourtinIndianapolis,Indiana....ectwhiletheUnitedStatesPatentandTrademarkOffice(US...
(Date:11/24/2009)...,, SANDIEGO,Nov.24/PRNewswire-FirstCall/--An...daythatitwillpresentatthe21stAnnualPiperJaffrayHea....EST(6:00a.m.PST).TheconferenceisbeingheldatTheNew...efExecutiveOfficerofAnadys,willprovideanoverviewof...NA773. ,, Thecorporatepresentationwillbesimulta...
(Date:11/24/2009)...,, PLEASANTON,Calif.,Nov.24/PRNewswire-First...aderindevice-basedmechanicalcirculatorysupportther...aythatitwillbeparticipatinginthe21stAnnualPiperJaf... DavidV.Smith,executivevicepresidentandchieffinanc...ngat8:30a.m.,EasternStandardTime(5:30a.m.,PacificS...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 1Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 2Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 3Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 4Mayo Clinic study continues to refine most effective methods to predict Alzheimers disease 51628 1Mayo Clinic study continues to refine most effective methods to predict Alzheimers disease 51628 2Elsevier partners with the Royal Colleges of Surgeons of Edinburgh and Ireland 51626 1Elsevier partners with the Royal Colleges of Surgeons of Edinburgh and Ireland 51626 2
...t, NutriSystem D Leads to Weight Loss, Lower Blood...1 NutriSystem (Nasdaq: NTRI ), a leading weight...nounced the launch of new NutriSystem D, a weight ...mately 24 million Americans with diabetes, as well...iabetes. , , In a clinical study at Temple Uni...
...ntial clinical trial strategies for personalized a... Systems Medicine, LLC (SM), a wholly-owned subsi... MTA: CTIC), presented data from a preclinical stu...informatics to identify genetic markers - "context...response to the experimental drug candidate brosta...
Other Medicine Technology:New Weight Loss Hope for People with Diabetes 2New Weight Loss Hope for People with Diabetes 3New Weight Loss Hope for People with Diabetes 4New Weight Loss Hope for People with Diabetes 5New Weight Loss Hope for People with Diabetes 6Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
(Date:11/25/2009)..., SILVERSPRING,Md.,Nov.25/PRNewswire-USNewswire...sCenterforDrugEvaluationandResearch,titled"ADiffic...pearsintheNov.26,2009issueofTheNewEnglandJournalof...bin/prnh/20090824/FDALOGO ) ,, Inthearticle,Woo...esstopainmedicationforthosewhoneeditandmanagingthe...
(Date:11/25/2009)...esearchers have found evidence of a statistically ...en among patients whose estrogen receptor (ER)-pos... ER-alpha; at serine-118 (ER-alpha S118-P), accord...mber 25 in the Journal of the National Cancer Ins...s are resistant to tamoxifen. Preclinical studies ...
(Date:11/25/2009)... Evaluation and treatment cl... Woodstock (Vocus) November 25, 2009 -- Ce...asal vaccines and H1N1 vaccine shots at four Cente...nother shipment of vaccine has arrived. The clinic...Lake and McHenry and will be open as follows: , ...
(Date:11/25/2009)..., ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--...eventHealthCareFraudActof2009,"S.2128,whichisdesig...etopreventfraudinMedicare.ThebillwasintroducedbySe...insseveralprovisionstheAmericanAssociationforHomec...theAssociationproposedtoCongressinFebruary.Thosepr...
(Date:11/25/2009)...mice, disks placed under the skin kill tumor cells...althDay News) -- A cancer vaccine delivered in a f...in mice, a new study reports. , The method uses...are loaded with tumor-specific antigens and implan...to attack tumors. The Harvard University scientist...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...ree studies presented at the 71st Annual Scientifi...ogy demonstrated that transoral endoscopic surgica... cavities such as the nose and mouth – can be succ...initial weight loss. Transoral gastroplasty...
...recent study conducted at Stanford University publ...s that a prospective new treatment is at hand to ... termed as ‘tennis elbow’ or ‘golfer’s elbow to av...clay courts. This ailment starts with the degenera...
...recent study has shown that the risk of cancer is ... mice, it was observed that when mice lost a bit o..., even when the weight loss was not the result of ...f the superfluous fat from some mice and subjected...
... has been noted worldwide that a stay at any healt...d infections which can complicate matters causing ....A recent survey done in Canada revealed that one-...cked up during a course of treatment at a health ...
... Kumbaribill, a neglected village nestled near the...nj district, deaths due to malnutrition and diseas...nt apathy," lamented a villager. "We are poor and ...d out, according to Grassroots Features. "L...
...recent survey conducted by Irish Examiner/Landsdow... that two out of three women in Ireland are unhapp...try and feels that there is definitely room for im...pects of the antenatal care that they received and...
Other Medicine News:Health News:New, Minimally-Invasive Surgery for the Morbidly Obese 2Health News:New, Minimally-Invasive Surgery for the Morbidly Obese 3Health News:Tribals in the Brink of Extinction due to Malnutrition and Diseases 2Health News:Tribals in the Brink of Extinction due to Malnutrition and Diseases 3Health News:'Ire' of Irish Moms pained over maternity services in Ireland. 2
Velcro Adjustable
Breast Overlay
Gonad shield set
Half Apron
Medicine Products: